Holen Sie sich die Stockscreener-App
0.4304
5.39%
-0.0245
Handel nachbörslich:
.43
-0.0004
-0.09%
Schlusskurs vom Vortag:
$0.4549
Offen:
$0.449
24-Stunden-Volumen:
769.49K
Relative Volume:
0.10
Marktkapitalisierung:
$18.73M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.83M
KGV:
-0.5448
EPS:
-0.79
Netto-Cashflow:
$-20.87M
1W Leistung:
-23.24%
1M Leistung:
-35.38%
6M Leistung:
-32.11%
1J Leistung:
-78.48%
1-Tages-Spanne:
$0.43
$0.4735
1-Wochen-Bereich:
$0.43
$0.615
52-Wochen-Spanne:
$0.34
$2.95
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Firmenname
Cognition Therapeutics Inc
Sektor
Branche
Telefon
412-481-2210
Adresse
2403 SIDNEY STREET, PITTSBURGH
Vergleichen Sie CGTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
0.4304 | 18.73M | 0 | -22.83M | -20.87M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2024-07-30 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-11-03 | Eingeleitet | B. Riley Securities | Buy |
| 2021-11-03 | Eingeleitet | Oppenheimer | Outperform |
Cognition Therapeutics Inc Aktie (CGTX) Neueste Nachrichten
Chardan Capital Reaffirms Buy Rating for Cognition Therapeutics (NASDAQ:CGTX) - Defense World
Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD - The Bakersfield Californian
Can Cognition's Zervimesine Tackle Dry AMD? New Research Reveals Promising Cellular Rescue - StockTitan
Cognition Therapeutics Reports Positive Futility Analysis Of Zervimesine In Geographic Atrophy - Nasdaq
Zervimesine shows promise in Phase 2 trial for dry AMD By Investing.com - Investing.com South Africa
Zervimesine shows promise in Phase 2 trial for dry AMD - Investing.com
Cognition Therapeutics Successfully Passes Pre-defined - GlobeNewswire
Cognition Therapeutics Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of ... - The Bakersfield Californian
Can This Small Biotech's Drug Tackle Both Eye Disease AND Alzheimer's? Phase 2 Data Says Yes - StockTitan
Cognition Therapeutics, Inc. to Co-Host Precision Medicine Workshop at Neuroimmunology Drug Development Summit - Nasdaq
Cognition Therapeutics’ VP of Research Co-hosting Precision - GlobeNewswire
Can This Biomarker Strategy Revolutionize Alzheimer's Treatment? Cognition's 95% Improvement Data - StockTitan
Cognition Therapeutics Announces Publication of Commercial - GlobeNewswire
Cognition Therapeutics develops new drug manufacturing process By Investing.com - Investing.com Nigeria
Cognition Therapeutics develops new drug manufacturing process - Investing.com India
Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead ... - The Bakersfield Californian
Inside Cognition's Game-Changing Manufacturing Process: Will This Transform Alzheimer's Drug Production? - StockTitan
37,108 Shares in Cognition Therapeutics, Inc. (NASDAQ:CGTX) Acquired by SG Americas Securities LLC - Defense World
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Recommendation of “Buy” from Brokerages - Defense World
BIO CEO 2025: Cognition CEO debates policy while advancing CT-1812 - BioWorld Online
B. Riley Cuts Earnings Estimates for Cognition Therapeutics - Defense World
Investors in cash trouble should check out Cognition Therapeutics Inc (CGTX) - SETE News
B. Riley Adjusts Cognition Therapeutics Price Target to $2 From $1.50, Maintains Buy Rating - Marketscreener.com
Cognition Therapeutics Presents Phase 2 Results For Drug To Fight DLB At International Conference - Nasdaq
Cognition Therapeutics Inc (CGTX) receives a Buy rating from B. Riley Securities - Knox Daily
What technical indicators reveal about CGTX stock - US Post News
Director Makes Bold Move with Major Stock Purchase in Cognition Therapeutics - TipRanks
Can Cognition Therapeutics Inc Bounce Back? 52-Week Performance and Analyst Predictions - The InvestChronicle
Is Now The Time To Buy Cognition Therapeutics Inc (NASDAQ: CGTX) Stock? - Stocks Register
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Short Interest Update - Defense World
A Data-Based Look At Cognition Therapeutics Inc (CGTX) - Stocks Register
Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine - GlobeNewswire
CGTXCOGNITION THERAPEUTICS INC Latest Stock News & Market Updates - StockTitan
Cognition Therapeutics Reports Positive Topline Results of Zervimesine in SHIMMER Study for Dementia with Lewy Bodies - Nasdaq
Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy - The Bakersfield Californian
New Dementia Drug Achieves Remarkable 91% Reduction in Cognitive FluctuationsPhase 2 Results Revealed - StockTitan
Brokers Issue Forecasts for CGTX FY2024 Earnings - Defense World
Lewy Body Dementia Market Deep Research Report with Forecast - openPR
Cognition Therapeutics (NASDAQ:CGTX) Raised to “Strong-Buy” at Brookline Capital Management - Defense World
70+ Key Companies Advancing in Dry Age-Related Macular Degeneration Clinical Trial Therapeutic Space | DelveInsight - The Malaysian Reserve
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Alzheimer's Disease Clinical and Non-Clinical Studies, Key - openPR
**Cognition Therapeutics (NASDAQ:CGTX) Prepares to Advance Treatment Efforts** ** - Defense World
Dry Age Macular Degeneration Pipeline Insights 2024: Therapies, Clinical Trials, Therapies and Key Companies involved by DelveInsight |Janssen R&D, Belite Bio, Katairo, Cognition Therapeutics - Barchart
Dry Age Macular Degeneration Pipeline Insights 2024: - openPR
Cognition Therapeutics Shows Promising Phase 2 Study Results - TipRanks
Cognition Therapeutics Is Targeting A Critical Form Of Dementia - Nasdaq
Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences - The Manila Times
Cognition Therapeutics Advances DLB Treatment After Positive Phase 2 Results, CEO to Present at JPM Week - StockTitan
Cognition Therapeutics (NASDAQ:CGTX) versus Editas Medicine (NASDAQ:EDIT) Head-To-Head Contrast - Defense World
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Finanzdaten der Cognition Therapeutics Inc-Aktie (CGTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.45%
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):